Integrating HIV Pre-Exposure Prophylaxis (PrEP) Education During Medical Residency: Training Outcomes and Suggestions for Learning Effectiveness
- PMID: 37933559
- PMCID: PMC10631327
- DOI: 10.1177/21501319231207313
Integrating HIV Pre-Exposure Prophylaxis (PrEP) Education During Medical Residency: Training Outcomes and Suggestions for Learning Effectiveness
Abstract
Human immunodeficiency virus (HIV) infection is now preventable with pre-exposure prophylaxis (PrEP) drugs, however, barriers to PrEP implementation include primary-care physician (PCP) knowledge-gap and lack of comfort prescribing and managing PrEP. We hypothesized that integrating HIV-PrEP education during medical-residency would help address these problems and developed a 40-minute case-based lecture focused on the 2021 United States Preventative Services Taskforce (USPSTF) oral HIV-PrEP guidelines and integrated this into our residency's core curriculum. We analyzed data from physician-trainees who voluntarily completed a pre- and post-lecture survey measuring HIV-PrEP "knowledge" and "self-assessed readiness to independently initiate and manage PrEP." Independent group analysis was completed via the Mann-Whitney U and Pearson Chi-square 2-sided test with P-value <0.05 deemed significant. Of the total of 189 residents invited to the lecture, 130 (69%) completed the pre-survey while 107 (57%) completed the post-survey. Per knowledge-assessment: the median number of correctly answered questions rose from a pre-lecture baseline of 4/9 (44%) to 8/9 (89%) following the education intervention (P < .001). When asked about comfort initiating and managing HIV-PrEP on their own, 7/130 (5.4%) responded in agreement pre-lecture, but this rose to 55/107 (51.4%) post-lecture (P < .001). Our study revealed PrEP training during residency was effective per stated objectives and may be an important tool to increase PrEP delivery/uptake to achieve the target goals for the National HIV/AIDS Strategy.
Keywords: HIV infections/prevention and control; anti-HIV agents/therapeutic use; education; graduate; medical; physicians; pre-exposure prophylaxis; primary care.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
References
-
- CDC. US public health service: preexposure prophylaxis for the prevention of HIV infection in the United Stated– 2021 updated. 2021. Accessed June 8, 2021. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
-
- U.S. Food & Drug Administration. FDA approves first injectable treatment for HIV pre-exposure prevention. 2021. Accessed June 8, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-i...
-
- US HIV Data & Trends. U.S. statistics. 2019. Accessed April 29, 2021. https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics
-
- CDC. HIV surveillance report. Diagnoses of HIV Infection in the United States and Dependent Areas, 2019. 2019. Accessed April 29, 2021. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveil...
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
